Also, IGF1 serum levels at third week of life were significantly lower in those patients who developed bronchopulmonary dysplasia, needed any kind of mechanical ventilation or oxygen support, patent ductus arteriosus, sepsis in the first 3 weeks of life, EPO treatment or needed transfusion. The gene discussed is EPO; the disease is bronchopulmonary dysplasia.